https://scholars.lib.ntu.edu.tw/handle/123456789/633533
標題: | Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer | 作者: | Paluch-Shimon, Shani Neven, Patrick Huober, Jens Cicin, Irfan Goetz, Matthew P Shimizu, Chikako CHIUN-SHENG HUANG et al., |
關鍵字: | abemaciclib; early breast cancer; high risk; monarchE; premenopausal | 公開日期: | 2023 | 卷: | 15 | 來源出版物: | Therapeutic advances in medical oncology | 摘要: | Abemaciclib is the first and only cyclin-dependent kinases 4 and 6 inhibitor approved for adjuvant treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, and high-risk early breast cancer (EBC), with indications varying by geography. Premenopausal patients with HR+, HER2- tumors may have different tumor biology and treatment response compared to postmenopausal patients. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633533 | ISSN: | 1758-8340 | DOI: | 10.1177/17588359231151840 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。